Mursla Bio’s AI Precision Medicine Platform to inform drug development and patient stratification in metabolic liver disease

Cambridge, UK, and Boston MA, USA, 13 November 2025: Mursla Bio, a leader in Extracellular Vesicle (EV) science on a mission to advance precision diagnostics and significantly improve chronic disease outcomes for at-risk patients, today announced a collaboration with a leading global pharmaceutical company recognized for its expertise in precision medicine and biomarker-guided drug development.

Under the collaboration, Mursla Bio’s AI Precision Medicine Platform will generate hepatocyte-specific extracellular vesicle (h-EV) profiles from blood samples collected from a well-characterized cohort of patients with metabolic dysfunction-associated steatohepatitis (MASH) and matched healthy controls. The collaboration will explore mode-of-action (MoA)-related biomarkers and evaluate biomarker panels to identify patients most likely to benefit from the pharmaceutical company’s investigational therapy.

The initial phase will focus on generating insights into liver tissue biology in MASH by building tissue-labeled, high dimensional mRNA and protein datasets from h-EVs in blood. This data will help define MoA-related pathways and patient stratification signatures, while strengthening Mursla Bio’s AI liver disease models developed through its MEV01 clinical study¹ and extending their applicability across future programs.

Complementing Mursla Bio’s lead product, EvoLiver™¹, developed for liver cancer surveillance among cirrhotic patients, the partnership broadens the clinical and translational reach of its clinically validated platform across metabolic liver diseases. The same infrastructure that enabled EvoLiver™ to achieve FDA Breakthrough Device Designation² will be used to accelerate the translation of exploratory biomarkers into regulatory-grade companion diagnostics.

Pierre Arsène, Founder and CEO of Mursla Bio, said: “This collaboration reflects the growing demand from global pharmaceutical leaders for our AI Precision Medicine Platform. As the GLP-1 revolution reshapes obesity management, MASH is rapidly emerging as the next major therapeutic focus, and the need for precise liver-specific biomarkers has never been greater. By profiling intact hepatocyte biology protected within the cargo of h-EVs, we are enabling a new generation of biomarker-guided precision medicine in liver care. This partnership deepens our reach in hepatology, expanding on the foundation established with EvoLiver.”

MASH is an advanced stage of fatty liver disease, strongly associated with the global rise in obesity and type 2 diabetes³. MASH affects 5-7% of the world’s adult population with more than 75% of those classed as overweight, obese, and living with type 2 diabetes⁴. It is characterized by the buildup of excess fat in the liver, which causes inflammation and cell damage. MASH can progress to irreversible scarring (cirrhosis) and, in some cases, lead to liver failure or liver cancer.

Financial details were not disclosed.

1. EvoLiver™ and MEV01
2. Press release: Mursla Bio receives FDA Breakthrough Device Designation for EvoLiver™ test
3. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association
4. Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases

ENDS

About Mursla Bio www.mursla.com

Mursla Bio is a biotech company on a mission to significantly improve chronic disease outcomes for at-risk patients through the power of Dynamic Biopsy. The Company’s proprietary biopsy platform non-invasively analyzes living biological processes within a specific organ or tissue to assess its health condition. This approach combines the accuracy and disease sub-typing capabilities of tissue biopsies with the ease of liquid biopsy sample collection.

Dynamic Biopsy is made possible by advanced extracellular vesicle (EV) science and an innovative approach called extracellular omics, supported by Mursla Bio’s pioneering technologies. These technologies include physical organ-specific EV isolation from biofluids for precise targeting, an AI-enabled multi-omics workflow spanning across proteins, miRNAs and mRNAs and a scalable clinical assay platform optimized for clinical validity and utility.

The Company’s AI Precision Medicine Platform underpins this technology, offering a full-stack infrastructure for biomarker discovery, assay development, and precision diagnostic productization across disease areas, grounded in real-world clinical datasets rather than static tissue atlases.

Mursla Bio is initially focused on transforming the surveillance of liver cancer in high-risk populations - the fastest growing cause of cancer related deaths. Mursla Bio is developing its first Dynamic Biopsy-based blood test, EvoLiver™ alongside synergistic precision medicine applications.

Mursla Bio is based in Cambridge, UK and Boston, MA.

For more information please visit: www.mursla.com